EU Advisory Body Aims to Reduce Bone Drug Osteonecrosis Risk EU Advisory Body Aims to Reduce Bone Drug Osteonecrosis Risk
The European Medicines Agency's pharmacovigilance panel advises new product labeling and patient reminders about the osteonecrosis risk with zoledronic acid, with future plans to target other bone drugs. News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 13, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
Reclast May Protect Bone by Reversing Marrow Fat
(MedPage Today) -- Early zoledronic acid reverses bone marrow adipogenesis during estrogen deficiency. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - January 7, 2015 Category: Endocrinology Source Type: news
Disseminated prostate cancer cells in bone
Most castrate-resistant prostate cancer patients develop bone metastases, and standard androgen deprivation therapy causes bone loss. Whether this treatment-induced bone microenvironment change affects disseminated tumour cells, thereby stimulating bone metastasis development, is not known. Ottewell and colleagues used an in vivo model to mimic androgen ablation, finding increased bone resorption and loss of bone volume, compared with controls. In addition, the growth and metastasis of disseminated tumour cells was triggered. Weekly administration of zoledronic acid prevented this tumour growth, but did not elimi...
Source: Society for Endocrinology - October 21, 2014 Category: Endocrinology Source Type: news
Who Needs Zoledronic Acid in Early Breast Cancer?Who Needs Zoledronic Acid in Early Breast Cancer?
Dr. Lidia Schapira describes the role of adjuvant bisphosphonates in early breast cancer as unclear, but suggests that host factors may prove key to efficacy. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 29, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news
Prostate Cancer and Zoledronic Acid: Two Emerging PatternsProstate Cancer and Zoledronic Acid: Two Emerging Patterns
The phase 3 RADAR trial looking at zoledronic acid in prostate cancer suggests 2 emerging standards of care, depending on Gleason score. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 29, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Bisphosphonates Not Associated with Reduced Breast Cancer Risk (FREE)
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
The bisphosphonates alendronate and zoledronic acid do not reduce the risk for breast cancer among postmenopausal women, according to findings from two randomized trials … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 11, 2014 Category: Primary Care Source Type: news
ASCO: OK to Cut Back on Bone Mets Therapy
CHICAGO (MedPage Today) -- Less frequent dosing of zoledronic acid (Zometa) after the first year in breast cancer metastatic to the bone was just as good for preventing skeletal events with potentially less toxicity, a trial showed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 31, 2014 Category: Hematology Source Type: news
Breast Cancer With Bone Mets: Less Zoledronic Acid Is FineBreast Cancer With Bone Mets: Less Zoledronic Acid Is Fine
Women with breast cancer and bone metastasis can scale back on the use of a bone-building drug over time and apparently still get the same benefit, new research suggests. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 30, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Women with metastatic breast cancer can safely receive bisphosphonates less frequently, without compromising care
Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration. With that practice change, women may also reduce their risk of serious side effects, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 30, 2014 Category: Science Source Type: news
Women with metastatic breast cancer can safely receive bisphosphonates less frequently, without comp
(University of Texas M. D. Anderson Cancer Center) Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration. With that practice change, women may also reduce their risk of serious side effects, according to a study led by researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 30, 2014 Category: Cancer & Oncology Source Type: news
Women with metastatic breast cancer can safely receive bisphosphonates less frequently, without compromising care
Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid,
less often after the first year of monthly administration. With that
practice change, they may also reduce their risk of serious side
effects, according to a study led by researchers at The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - May 30, 2014 Category: Cancer & Oncology Source Type: news
Efficacy of Zoledronic Acid for Chronic Low Back PainEfficacy of Zoledronic Acid for Chronic Low Back Pain
Zoledronic acid may offer another therapeutic option for patients with chronic low back pain and MRI-identified Modic changes, a new study suggests. BMC Musculoskeletal Disorders (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - May 8, 2014 Category: Orthopaedics Tags: Orthopaedics Journal Article Source Type: news
No Benefit to Earlier Use of Bone Drug in Prostate CancerNo Benefit to Earlier Use of Bone Drug in Prostate Cancer
Use of zoledronic acid for castration-sensitive prostate cancer does not decrease the risk for skeletal events, compared with treatment started after progression to castration-resistant disease. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 6, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Zoledronate vs Ibandronate for Patients With Bone MetastasesZoledronate vs Ibandronate for Patients With Bone Metastases
Zoledronic acid is better than ibandronic acid for preventing skeletal events caused by bone metastases, according to new research. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 31, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Comparison of side effects, efficacy of osteoporosis drugs
A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms. These findings were presented recently at the American Society for Bone and Mineral Research's annual meeting. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 5, 2013 Category: Consumer Health News Tags: Bones / Orthopedics Source Type: news
